somatropin + leuprorelin
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Short Stature (ISS)
Conditions
Idiopathic Short Stature (ISS)
Trial Timeline
Jun 1, 2006 โ Jul 1, 2015
NCT ID
NCT00355030About somatropin + leuprorelin
somatropin + leuprorelin is a phase 3 stage product being developed by Eli Lilly for Idiopathic Short Stature (ISS). The current trial status is completed. This product is registered under clinical trial identifier NCT00355030. Target conditions include Idiopathic Short Stature (ISS).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00355030 | Phase 3 | Completed |
Competing Products
20 competing products in Idiopathic Short Stature (ISS)